Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)
In the Phase 2 study, the incidence of treatment-emergent adverse events was similar to placebo, and no unexpected safety signals were identified
In mUMSARS scores and MRI-based brain volume assessment (vMRI), a tendency toward suppressed disease progression was observed compared to the placebo group
Based on the results of the Phase 2 study, a pivotal Phase 3 study will be initiated
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced the presentation of data from the randomized, double-blind, placebo-controlled, Phase 2 study of ONO-2808（ONO-2808-03 study）for the treatment of multiple system atrophy (MSA) at the 7th World Parkinson Congress, held from May 24 to May 27, 2026, in Phoenix, Arizona, USA.
